TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06134089

Intervention type: BEHAVIORAL
Intervention: Perceived Effectiveness Prompt
Description: Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented.

Intervention type: BEHAVIORAL
Intervention: Perceived Effectiveness Prompt
Description: Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented.

Intervention type: BEHAVIORAL
Intervention: Perceived Shareability Prompt
Description: Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented.

Intervention type: BEHAVIORAL
Intervention: Perceived Shareability Prompt
Description: Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented.
Study: NCT06419777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used in gestational diabetics to control blood glucose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used in gestational diabetics to control blood glucose levels
Study: NCT06119711

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05829525

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of sleep quality, sleep duration, heart rate and step count
Description: Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
Study: NCT04565028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
Study: NCT06373835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emodepside
Description: 5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
Study: NCT05990452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2921
Description: All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
Study: NCT05646004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Implantation of 621 lens
Study: NCT04986111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Linear skin closure with wound drain
Description: An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse-string skin closure with negative pressure wound therapy
Description: Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread.
Study: NCT05421546

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spermidine or Placebo
Description: The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spermidine or Placebo
Description: The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
Study: NCT04570228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary artery denervation
Description: The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
Study: NCT05900258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin
Description: Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
Study: NCT06444997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
Study: NCT06322173

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS Analysis
Description: An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
Study: NCT05171985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Description: 72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dexmedetomidine sedation
Description: 72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
Study: NCT06437639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexidol
Description: Neurocytoprotector
Study: NCT04878276

Intervention type: DEVICE
Intervention: Dimet 5
Description: The application is carried out according to the enclosed instructions for use.

Intervention type: DEVICE
Intervention: Dimet 5
Description: The application is carried out according to the enclosed instructions for use.
Study: NCT06392178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SugarVita
Description: Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
Study: NCT05865756

Intervention type: OTHER
Group type: OTHER
Intervention: Acoustic cough features analysis
Description: Acoustic cough features analysis
Study: NCT06287931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodoxycholic acid group
Description: Ursodoxycholic acid, 250mg po tid x 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodoxycholic acid group
Description: Ursodoxycholic acid, 250mg po tid x 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium group
Description: Bifidobacteria, 210 mg po tid x 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium group
Description: Bifidobacteria, 210 mg po tid x 6 months
Study: NCT04692233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Baduanjin
Description: Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light flexibility exercise
Description: Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
Study: NCT05829915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROXPro© system (A-Champs)
Description: The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise program
Description: The control group did not received the physical exercise program
Study: NCT04745247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSS
Description: Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: RSS
Description: Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS
Study: NCT05255627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application group (Experimental Group)
Description: A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature.
Study: NCT06120049

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [123I]-MIBG SPECT CT
Description: \[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [123I]-MIBG SPECT CT
Description: \[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq
Study: NCT05832060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS or tDCS
Description: Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tRNS or tDCS
Description: Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
Study: NCT05870397

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times
Description: Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times
Description: Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times
Description: Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
Study: NCT05656118

Intervention type: DEVICE
Intervention: Genoss® DCB
Description: Paclitaxel coated balloon with a shellac plus vitamin E excipient
Study: NCT05064540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alto Abdominal Stent Graft System
Description: Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved EVAR AAA Graft Systems
Description: FDA approved comparator of choice
Study: NCT06120049

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [123I]-MIBG SPECT CT
Description: \[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-MFBG PET dosimetry scans
Description: \[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation.
Study: NCT06201403

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of biomechanical properties of muscles
Description: All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of biomechanical properties of muscles
Description: All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine
Study: NCT05698004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prone positioning
Description: The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
Study: NCT06076239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT Group
Description: EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT Group
Description: EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
Study: NCT04935567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statistical model for the prediction of VNS efficacy
Description: statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statistical model for the prediction of VNS efficacy
Description: statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data